1.02

7.27% -0.08

After Hours: 1.06 0.04 +3.92%

Karyopharm Therapeutics Inc (KPTI)

Overview News Price History Option Chain Financials Discussions Forecast

Karyopharm Therapeutics Inc stock is currently priced at $1.02, with a 24-hour trading volume of 2.63M. It has seen a -7.27% decreased in the last 24 hours and a -24.44% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.13 pivot point. If it approaches the $0.9501 support level, significant changes may occur.

Previous Close:

$1.10

Open:

$1.13

24h Volume:

2.63M

Market Cap:

$133.35M

Revenue:

$146.03M

Net Income/Loss:

$-143.10M

P/E Ratio:

-0.7727

EPS:

-1.32

Net Cash Flow:

$-92.72M

1W Performance:

-5.56%

1M Performance:

-24.44%

6M Performance:

+36.00%

1Y Performance:

-59.20%

1D Range:

$1.02

$1.20

52W Range:

$0.6174

$2.79

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name

Karyopharm Therapeutics Inc

Sector

Healthcare (1217)

Industry

Biotechnology (698)

Phone

617-658-0600

Address

85 Wells Avenue, 2nd Floor, Newton, MA

Employee

154

Twitter

@Karyopharm

Next Earnings Date

2024-05-29

Latest SEC Filings

KPTI's Discussions on Twitter

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-19-23	Initiated	Piper Sandler	Overweight
Nov-04-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-09-22	Upgrade	JP Morgan	Underweight → Neutral
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral
Aug-06-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-06-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-02-20	Initiated	Morgan Stanley	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Jul-23-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-05-19	Reiterated	H.C. Wainwright	Buy
Jul-05-19	Reiterated	Robert W. Baird	Outperform
Mar-01-19	Downgrade	JP Morgan	Overweight → Neutral
Feb-28-19	Reiterated	BofA/Merrill	Underperform
Feb-27-19	Downgrade	BofA/Merrill	Neutral → Underperform
Jan-03-19	Upgrade	BofA/Merrill	Underperform → Neutral
Dec-03-18	Initiated	B. Riley FBR	Buy
Nov-09-18	Upgrade	Wedbush	Neutral → Outperform
May-24-18	Downgrade	Wedbush	Outperform → Neutral
Apr-02-18	Resumed	Leerink Partners	Outperform
Nov-15-17	Resumed	H.C. Wainwright	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Sep-08-16	Reiterated	H.C. Wainwright	Buy
Aug-30-16	Upgrade	Jefferies	Hold → Buy
Aug-18-16	Initiated	H.C. Wainwright	Buy
Jun-28-16	Initiated	Robert W. Baird	Outperform

View All

Karyopharm Therapeutics Inc Stock (KPTI) Latest News

Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know

Zacks Investment Research

5 Russell 2000 Stocks Poised to Give the Large Caps a Run for Their Money

Investing.com

Karyopharm Therapeutics Inc Stock (KPTI) Financials Data

Karyopharm Therapeutics Inc (KPTI) Revenue 2024

KPTI reported a revenue (TTM) of $146.03 million for the quarter ending December 31, 2023, a -7.03% decline year-over-year.

Karyopharm Therapeutics Inc (KPTI) Net Income 2024

KPTI net income (TTM) was -$143.10 million for the quarter ending December 31, 2023, a +13.43% increase year-over-year.

Karyopharm Therapeutics Inc (KPTI) Cash Flow 2024

KPTI recorded a free cash flow (TTM) of -$92.72 million for the quarter ending December 31, 2023, a +38.05% increase year-over-year.

Karyopharm Therapeutics Inc (KPTI) Earnings per Share 2024

KPTI earnings per share (TTM) was -$1.25 for the quarter ending December 31, 2023, a +38.42% growth year-over-year.

Karyopharm Therapeutics Inc Stock (KPTI) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Rangwala Reshma	EVP & Chief Medical Officer	Apr 22 '24	Sale	1.17	6,789	7,943	342,931
Paulson Richard A.	President and CEO	Apr 04 '24	Sale	1.29	3,563	4,596	1,157,273
Paulson Richard A.	President and CEO	Mar 05 '24	Sale	1.30	3,573	4,645	1,160,836
Paulson Richard A.	President and CEO	Mar 01 '24	Sale	1.20	19,374	23,249	1,164,409
Mason Michael	EVP, CFO & Treasurer	Mar 01 '24	Sale	1.20	6,162	7,394	398,756
Poulton Stuart	EVP, Chief Development Officer	Mar 01 '24	Sale	1.20	6,155	7,386	329,511
Rangwala Reshma	EVP & Chief Medical Officer	Mar 01 '24	Sale	1.20	5,969	7,163	349,720
Cheng Sohanya Roshan	EVP & Chief Commercial Officer	Mar 01 '24	Sale	1.20	5,109	6,131	393,509
Mano Michael	SVP, General Counsel&Secretary	Mar 01 '24	Sale	1.20	3,576	4,291	277,852
Paulson Richard A.	President and CEO	Feb 29 '24	Sale	1.17	80,470	94,150	1,183,783

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma. The company is also developing KPT-8602 that is in Phase 1/2 study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.